Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMD

Video

Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Related Content
A glass building with a sign reading "RESERVE BANK." There are $100 Australian bank notes superimposed over the image. Concept image for Mirugen funding, cell reprogramming biologic biotech business of retina care news. Image credit: ©Rose Makin – stock.adobe.com

Australian biotech firm Mirugen secures major funding for cell reprogramming therapy

Hattie Hayes
August 19th 2025
Article
A photo of the European Medicines Agency (EMA) headquarters. Concept image for Alteogen aflibercept biosimilar approval, Committee for Medicinal Products for Human Use CHMP positive opinion for EYLUXVI. Image credit: ©Ogulcan Aksoy - SCA – stock.adobe.com

Alteogen receives positive CHMP opinion for aflibercept biosimilar EYLUXVI

Martin David Harp
August 19th 2025
Article
Health Canada approves aflibercept biosimilar Aflivu

Health Canada approves aflibercept biosimilar Aflivu

Sydney M Crago
August 19th 2025
Article
A person sits at their laptop with a cup of coffee visible in the foreground. Concept image for instant coffee, AMD, age related macular degeneration, ocular health and instant coffee investigation. Image credit: ©Ljustina – stock.adobe.com

Patients with high genetic risk of AMD should avoid instant coffee, investigators say

Lynda Charters
August 19th 2025
Article
Scientists work in a lab, looking at microscopes while data is superimposed over the top of the photo. Concept image for clinical trial research and structural functional endpoints in ophthalmology. Image credit: ©metamorworks – stock.adobe.com

Imaging the ellipsoid zone line could change the global approach to clinical trials

Hattie Hayes;Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS
August 19th 2025
Article
The Agência de vigilância Sanitária (ANVISA) in Brazil. Concept image for pharmaceutical approval, Lucentis ranibizumab biosimilar ranivisio FYB201. Image credit: ©Rmcarvalhobsb – stock.adobe.com

Brazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

Lynda Charters
August 19th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.